Skip to main content
. 2020 Jun 15;28(11):2473–2487. doi: 10.1016/j.ymthe.2020.06.013

Figure 2.

Figure 2

Effect of lncAMPC Knockdown or Overexpression on Oncogenic Activities In Vitro

(A) MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay testing the cell proliferation of C4-2 and PC-3 transfected with NCsi, silncAMPC-1, or silncAMPC-2 (n = 3). (B) MTS assay testing the cell proliferation of LNCaP and 22Rv1 transfected with lncAMPC-OV (lncAMPC overexpression) or NC-OV (overexpression control) (n = 3). (C) Colony assay testing the cell viability of C4-2 and PC-3 transfected with NCsi, silncAMPC-1, or silncAMPC-2 (n = 3). (D) Colony assay testing the cell viability of LNCaP and 22Rv1 transfected with lncAMPC-OV or NC-OV (n = 3). (E) Transwell assay testing the cell migration and invasion of C4-2 and PC-3 transfected with NCsi, silncAMPC-1, or silncAMPC-2 (n = 3). (F) Transwell assay testing the cell migration and invasion of LNCaP and 22Rv1 transfected with lncAMPC-OV or NC-OV (n = 3). (G) The mRNA expression levels of EMT markers in PC-3 transfected with lncAMPC-OV or NC-OV (n = 3). (H) Cell immunofluorescence analysis of the localization and expression of EMT markers in PC-3 transfected with lncAMPC-OV or NC-OV. Results are presented as means ± SD. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.